Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319889 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02319889: Clinical Trial Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT02319889 is a Early Phase 1 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02319889, a Early Phase 1 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot clinical trial studies stereotactic body radiation therapy followed by combination chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body radiation therapy is a specialized radiation therapy that delivers one to five high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue than conventional radiation. Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving stereotactic body radiation therapy, followed by carboplatin, and paclitaxel albumin-stabilized nanoparticle formulation may kill more tumor cells and result in a better and more durable response than conventional radiation and chemotherapy. The purpose of this study is to test the safety of this approach prior to larger studies.
Primary Outcome
Number of participants that miss two or more cycles of treatment due to toxicities
Interventions
- DRUG Carboplatin
- RADIATION Stereotactic Body Radiotherapy
- DRUG Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2017-01-19 |
| Phase | Early Phase 1 |
Why NCT02319889 stopped before completion
NCT02319889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02319889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02319889 about?
NCT02319889 is a clinical study titled "Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma". This pilot clinical trial studies stereotactic body radiation therapy followed by combination chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body radiation therapy is a specialized radiation therapy that delivers one to five high doses of radiation directly to the tu...
What is the current status of trial NCT02319889?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2016-02-02. Estimated completion is 2017-01-19.
What interventions are being tested in trial NCT02319889?
The interventions under investigation include: Carboplatin (DRUG), Stereotactic Body Radiotherapy (RADIATION), Paclitaxel Albumin-Stabilized Nanoparticle Formulation (DRUG).
Who is sponsoring clinical trial NCT02319889?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02319889's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI